Markets

Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise

Photo of mrarup82 mrarup82January 24, 2025
0 1 Less than a minute


The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger. Read More

Photo of mrarup82 mrarup82January 24, 2025
0 1 Less than a minute
Photo of mrarup82

mrarup82

Related Articles

SEC Delays XRP and Solana ETF Approvals

2 weeks ago

Three reasons why this top AI stock surged 25% higher

February 14, 2025

Ethena (ENA) Price Shows Strength – Could This Be the Start of a Major Rally?

2 weeks ago

Utah’s Senate passes Bitcoin bill — but scraps key provision

2 weeks ago

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button